#Singapore #CBC Group #R-Bridge #Motiva

R-Bridge Healthcare Fund Secures Major Financing for Human Investments Ltd.

In a significant move for the healthcare sector, the R-Bridge Healthcare Fund, part of CBC Group, has announced a non-dilutive growth financing deal that could reach up to $50 million for Human Investments Ltd. This financing is set to enhance the market presence of Motiva® devices across Asia, particularly in Korea and China. The transaction signals the growing trend of investment in innovative healthcare solutions, reflecting a commitment to expanding access to quality healthcare technologies.

Strategic Focus on Motiva® Market Expansion

Human Investments Ltd., which operates through its subsidiaries Motiva Korea and Motiva China, has established a strong foothold as the exclusive distributor for Establishment Labs Holdings Inc. in these regions. The company has seen remarkable growth within just three years of Motiva's launch in Korea, where it has emerged as the leading brand in augmentation and reconstructive surgeries.

Dr. Michael Keyoung, the Senior Managing Director at CBC Group, expressed enthusiasm about the partnership with Human Investments Ltd., citing their successful market leadership in Korea's medical aesthetic and reconstruction field. This financing will support Human Investments in replicating its Korean success in both China and other Asian markets, where a demand for innovative feminine health solutions is rapidly growing.

Financing Details

The structure of the financing includes a synthetic royalty feature and availability tied to specific sales milestones. This approach not only provides the necessary funds for market expansion but also mitigates the risks typically associated with equity financing, allowing Human Investments to maintain their operational integrity while pursuing ambitious growth objectives.

Impact on Female Health in Asia

The Motiva devices, known for their safety and natural feel, are at the forefront of enhancing healthcare options for women. Known for using advanced 3D negative imprinting technology, these devices boast regulatory approvals in various key markets, including the recent nod from the U.S. FDA, which recognized them as the first new breast implant since 2013. The recent approval from the National Medical Products Administration (NMPA) has opened the doors for Motiva products in China, poised for a market entry that will contribute to the health and wellness of women there.

John Lim, founder and CEO of Human Investments Ltd., emphasized the company’s vision to not only lead but also innovate within the sector, aiming to position Motiva as a unique option among competitors. This financing from R-Bridge will allow Human Investments to amplify its operational capacity significantly, ensuring that it can meet the demands of a growing market.

About CBC Group

CBC Group stands as Asia's largest healthcare-focused asset management firm, with assets under management totaling around $9 billion. With an extensive portfolio that encompasses pharmaceutical developments to healthcare services, the firm remains committed to providing alternative financing options aimed at fostering innovation in healthcare.

The establishment of the R-Bridge Healthcare Fund in 2019 highlights the group's desire to generate sustainable returns while promoting advancements in healthcare technology in Asia. The fund is actively seeking to invest in companies that prioritize innovative healthcare solutions, stretching the geographical footprint of high-quality medical services.

In conclusion, the significant financing package from R-Bridge Healthcare Fund for Human Investments Ltd. marks a pivotal moment for the expansion of the Motiva® brand in Asia. As the market evolves with burgeoning demand for sophisticated healthcare products that cater to women's health, investments like these are crucial for fostering growth and accessibility in the industry.